CY1116256T1 - Il-17 ανταγωνιστικα αντισωματα - Google Patents

Il-17 ανταγωνιστικα αντισωματα

Info

Publication number
CY1116256T1
CY1116256T1 CY20151100401T CY151100401T CY1116256T1 CY 1116256 T1 CY1116256 T1 CY 1116256T1 CY 20151100401 T CY20151100401 T CY 20151100401T CY 151100401 T CY151100401 T CY 151100401T CY 1116256 T1 CY1116256 T1 CY 1116256T1
Authority
CY
Cyprus
Prior art keywords
antibody against
competitive antibodies
human
disorder
heavy
Prior art date
Application number
CY20151100401T
Other languages
English (en)
Inventor
Padova Franco E Di
Hermann Gram
Hans Hofstetter
Margit Jeschke
Jean-Michel Rondeau
Den Berg Wim Van
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32982602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116256(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1116256T1 publication Critical patent/CY1116256T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Δίδεται ένα μόριο δέσμευσης IL-17, συγκεκριμένα ένα αντίσωμα έναντι ανθρώπινης IL-17, κατά μεγαλύτερη προτίμηση ένα ανθρώπινο αντίσωμα έναντι IL-17, όπου οι υπερμεταβλητές περιοχές της βαριάς και ελαφράς αλυσίδας έχουν αλληλουχίες αμινοξέων, όπως ορίζονται για χρήση εις την αγωγή μίας IL-17-μεσολαβούμενης νόσου ή διαταραχής, π.χ. της ρευματοειδούς αρθρίτιδας.
CY20151100401T 2004-08-05 2015-05-07 Il-17 ανταγωνιστικα αντισωματα CY1116256T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417487.6A GB0417487D0 (en) 2004-08-05 2004-08-05 Organic compound
EP10174725.1A EP2366405B1 (en) 2004-08-05 2005-08-04 IL-17 antagonistic antibodies

Publications (1)

Publication Number Publication Date
CY1116256T1 true CY1116256T1 (el) 2017-02-08

Family

ID=32982602

Family Applications (6)

Application Number Title Priority Date Filing Date
CY20111100936T CY1111963T1 (el) 2004-08-05 2011-09-27 Ανταγωνιστικα αντισωματα il-17
CY20141100628T CY1115444T1 (el) 2004-08-05 2014-08-08 Ανταγωνιστικα αντισωματα il-17
CY20151100401T CY1116256T1 (el) 2004-08-05 2015-05-07 Il-17 ανταγωνιστικα αντισωματα
CY2015030C CY2015030I2 (el) 2004-08-05 2015-07-10 Ανταγωνιστικα αντισωματα il-17
CY181100727T CY1120723T1 (el) 2004-08-05 2018-07-11 Ανταγωνιστικα αντισωματα il-17
CY2018027C CY2018027I2 (el) 2004-08-05 2018-10-10 Ανταγωνιστικα αντισωματα il-17

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20111100936T CY1111963T1 (el) 2004-08-05 2011-09-27 Ανταγωνιστικα αντισωματα il-17
CY20141100628T CY1115444T1 (el) 2004-08-05 2014-08-08 Ανταγωνιστικα αντισωματα il-17

Family Applications After (3)

Application Number Title Priority Date Filing Date
CY2015030C CY2015030I2 (el) 2004-08-05 2015-07-10 Ανταγωνιστικα αντισωματα il-17
CY181100727T CY1120723T1 (el) 2004-08-05 2018-07-11 Ανταγωνιστικα αντισωματα il-17
CY2018027C CY2018027I2 (el) 2004-08-05 2018-10-10 Ανταγωνιστικα αντισωματα il-17

Country Status (39)

Country Link
US (8) US7807155B2 (el)
EP (5) EP2364729B3 (el)
JP (1) JP4682200B2 (el)
KR (2) KR20080029018A (el)
CN (1) CN101001645B (el)
AR (1) AR050200A1 (el)
AT (1) ATE517924T1 (el)
AU (2) AU2005268857C1 (el)
BR (3) BR122017009404B1 (el)
CA (1) CA2573586C (el)
CY (6) CY1111963T1 (el)
DK (4) DK2364729T6 (el)
EC (1) ECSP077198A (el)
ES (4) ES2536228T3 (el)
FR (1) FR15C0048I2 (el)
GB (1) GB0417487D0 (el)
HK (3) HK1101277A1 (el)
HR (3) HRP20110758T4 (el)
HU (4) HUE025815T2 (el)
IL (1) IL180717A (el)
LT (3) LT2902039T (el)
LU (2) LU92768I2 (el)
MA (1) MA28982B1 (el)
MX (1) MX2007001338A (el)
MY (1) MY144925A (el)
NL (1) NL300749I2 (el)
NO (9) NO336279B1 (el)
NZ (1) NZ552658A (el)
PE (1) PE20060418A1 (el)
PL (4) PL2366405T3 (el)
PT (4) PT1776142E (el)
RU (2) RU2426741C3 (el)
SG (1) SG155186A1 (el)
SI (4) SI2902039T1 (el)
TN (1) TNSN07034A1 (el)
TR (1) TR201808057T4 (el)
TW (1) TWI359153B (el)
WO (1) WO2006013107A1 (el)
ZA (1) ZA200700242B (el)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP2322219A3 (en) * 2005-09-01 2013-06-05 Merck Sharp & Dohme Corp. Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
EP3808769A1 (en) 2005-12-13 2021-04-21 Eli Lilly And Company Anti-il-17 antibodies
PL1964852T3 (pl) 2005-12-20 2013-09-30 Sbi Biotech Co Ltd Przeciwciało anty-ilt7
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
RU2430110C2 (ru) * 2006-01-31 2011-09-27 Новартис Аг Антитела - антагонисты интерлейкина-17 (ил-17) для лечения рака
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
BRPI0715917A2 (pt) * 2006-08-11 2014-11-25 Schering Corp Anticorpos para il-17a
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
CN101668531B (zh) 2007-02-28 2014-05-07 默沙东公司 用于治疗免疫病症的联合治疗
EP2152308A1 (en) 2007-05-29 2010-02-17 Novartis Ag New indications for anti- il-i-beta therapy
EP2171449A2 (en) * 2007-06-20 2010-04-07 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
WO2009015063A2 (en) * 2007-07-23 2009-01-29 Centocor Methods and compositions for treating fibrosis related disorders using il-17 antagonists
WO2009033091A1 (en) * 2007-09-06 2009-03-12 City Of Hope Treatment of th17-mediated autoimmune disease via inhibition of stat3
KR101616995B1 (ko) * 2007-12-03 2016-06-07 (주)아모레퍼시픽 슬리밍용 조성물
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
US9309313B2 (en) 2008-01-09 2016-04-12 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
CN102014958A (zh) 2008-04-29 2011-04-13 米克罗麦特股份公司 用于治疗的gm-csf和il-17抑制剂
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
NZ623706A (en) 2008-05-05 2015-12-24 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
UY31861A (es) 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
BRPI0915448A2 (pt) 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
BRPI0919531A2 (pt) * 2008-09-29 2015-12-08 Roche Glycart Ag anticorpos contra il17 humana e usos dos mesmos
KR101579771B1 (ko) 2009-03-05 2015-12-28 애브비 인코포레이티드 Ｉｌ-17 결합 단백질
CA2758290C (en) * 2009-04-27 2018-04-10 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
BRPI1014544B8 (pt) 2009-05-05 2021-05-25 Novimmune Sa anticorpo anti-il-17f monoclonal totalmente humano isolado e composição farmacêutica compreendendo o mesmo
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
JP2013507132A (ja) * 2009-10-10 2013-03-04 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ Ｉｌ−１７ファミリーサイトカイン組成物及び使用
WO2011047262A2 (en) 2009-10-15 2011-04-21 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EA029283B1 (ru) 2009-10-30 2018-03-30 Янссен Байотек, Инк. Антагонисты il-17a
US9932403B2 (en) 2010-05-20 2018-04-03 Ablynx Nv Biological materials related to HER3
PE20131412A1 (es) 2010-08-03 2014-01-19 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
CN103154026B (zh) * 2010-08-05 2016-07-06 安奈普泰斯生物有限公司 抗il-17的抗体
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
EP4137514A1 (en) 2010-10-08 2023-02-22 Novartis AG Methods of treating psoriasis using il-17 antagonists
KR20180019247A (ko) 2010-11-05 2018-02-23 노파르티스 아게 Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
AU2014259526B2 (en) * 2010-11-05 2016-02-04 Novartis Ag Methods of treating ankylosing spondylitis using IL-17 antagonists
TW201307845A (zh) 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
JP5947041B2 (ja) * 2011-01-07 2016-07-06 第一三共ヘルスケア株式会社 安全なｉｌ−１７産生抑制剤
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
EP2663869A1 (en) * 2011-01-13 2013-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cardiovascular event in a subject
SG191906A1 (en) 2011-01-14 2013-08-30 Ucb Pharma Sa Antibody molecules which bind il-17a and il-17f
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
EA028326B1 (ru) * 2011-03-29 2017-11-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Многокомпонентная буферная система для очистки рекомбинантного белка и способы очистки белка
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP4015005A1 (en) 2011-10-03 2022-06-22 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2015504430A (ja) * 2011-11-21 2015-02-12 ノバルティス アーゲー Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法
WO2013082282A1 (en) 2011-12-02 2013-06-06 lNOVARTIS AG Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease.
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
EP2791171A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
BR112014024903A2 (pt) 2012-04-05 2017-07-11 Hoffmann La Roche anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos
JP2015519311A (ja) 2012-04-20 2015-07-09 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを用いて強直性脊椎炎を治療する方法
EP3456741B1 (en) 2012-05-22 2020-12-16 Bristol-Myers Squibb Company Il-17a/f il-23 bispecific antibodies and their uses
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
TW202037609A (zh) 2012-11-01 2020-10-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
CN105073775B (zh) 2013-02-08 2019-03-19 诺华股份有限公司 抗-il-17a抗体及其在治疗自身免疫性和炎性病症中的用途
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014155278A2 (en) * 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
US10434172B2 (en) 2013-08-15 2019-10-08 Novartis Ag Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists
WO2015028657A1 (en) 2013-08-30 2015-03-05 Takeda Gmbh Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
LT3072905T (lt) 2013-11-18 2020-12-10 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-17a surišantis agentas ir jo panaudojimas
EP3101035B1 (en) * 2014-01-28 2021-10-06 Beijing Hanmi Pharmaceutical Co., Ltd. Bifunctional fusion protein, preparation method therefor, and use thereof
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
JP2017528465A (ja) 2014-09-10 2017-09-28 ノバルティス アーゲー 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ−１７アンタゴニストの使用
RU2609627C2 (ru) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
EP3245224B1 (en) 2015-01-12 2020-07-15 Affibody AB Il-17a-binding polypeptides
EP3250927B1 (en) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis
CN108251431B (zh) * 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
BR112017025264A2 (pt) 2015-07-16 2018-08-07 Lilly Co Eli tratamento de prurido
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
AU2016342578A1 (en) 2015-10-19 2018-03-29 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (IL-17) antagonists
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
US10307455B2 (en) 2016-03-10 2019-06-04 Acceleron Pharma Inc. Activin type 2 receptor antibodies
CA3017197A1 (en) 2016-03-10 2017-09-14 Viela Bio, Inc. Ilt7 binding molecules and methods of using the same
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
FR3051673B1 (fr) * 2016-05-24 2018-06-22 Assistance Publique - Hopitaux De Paris Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
EP3487881B1 (en) 2016-07-19 2024-08-21 Novartis AG Methods of treating new-onset plaque type psoriasis using il-17 antagonists
IL265350B1 (en) 2016-09-14 2024-06-01 Beijing hanmi pharm co ltd An antibody that specifically binds to IL-17A and its functional fragment
JP2019505516A (ja) 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
CR20190387A (es) 2017-02-10 2019-09-25 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
TW201842933A (zh) 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
CN108359011B (zh) 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
WO2019087133A1 (en) 2017-11-02 2019-05-09 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
US20200277369A1 (en) 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
CA3083949A1 (en) 2017-11-30 2020-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
US20210079087A1 (en) * 2018-03-29 2021-03-18 Remd Biotherapeutics, Inc. Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)
CR20200571A (es) 2018-06-01 2021-01-18 Novartis Ag Moléculas de únion contra bcma y usos de las mismas
WO2020024931A1 (en) * 2018-07-31 2020-02-06 Shen Weiqun Anti-il-17a antibodies and use thereof
EP3856772A1 (en) 2018-09-25 2021-08-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
MA54857A (fr) 2019-01-31 2021-12-08 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour tnfa et il-17a, anticorps ciblant il-17a, et leurs procédés d'utilisation
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
WO2020243504A1 (en) 2019-05-31 2020-12-03 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
CN114286827B (zh) 2019-07-26 2024-01-12 神州细胞工程有限公司 人源化抗il17a抗体及其应用
US20220267432A1 (en) 2019-07-30 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Method for treating autoimmune disease by il-17 antagonist
KR20220066318A (ko) 2019-09-20 2022-05-24 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용한 자가면역 질환의 치료 방법
CN114423455A (zh) * 2019-09-25 2022-04-29 国立大学法人东京大学 用于治疗系统性硬化症的药物组合物
WO2021067195A1 (en) 2019-09-30 2021-04-08 Janssen Biotech, Inc. Compositions and methods for an il-17 target engagement assay with large molecule modulators
US20230009657A1 (en) 2019-11-19 2023-01-12 Novartis Ag Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
AU2020396455A1 (en) 2019-12-06 2022-06-02 Novartis Ag Methods of treating lichen planus using Interleukin-17 (IL-17) antagonists
CN111040035B (zh) * 2019-12-31 2022-05-24 南京融捷康生物科技有限公司 针对il-17ra蛋白的抗体及其制备方法和应用
AU2021296436A1 (en) 2020-06-23 2023-02-02 Novartis Ag Methods of treating Thyroid Eye Disease and Graves' Orbitopahy using Interleukin-17 (IL-17) antagonists
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
JP2023548529A (ja) 2020-11-06 2023-11-17 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
CA3202877A1 (en) 2020-12-02 2022-06-09 Fresenius Kabi Deutschland Gmbh Methods of selectively reducing antibodies
IL303951A (en) 2020-12-22 2023-08-01 Novartis Ag Methods for reducing the oxidation level of cysteine residues in recombinantly secreted protein during cell culture
WO2023209519A1 (en) 2022-04-25 2023-11-02 Novartis Ag Crystalline forms of an il-17 inhibitor
WO2023223211A1 (en) 2022-05-16 2023-11-23 Novartis Ag Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
WO2023223263A1 (en) 2022-05-18 2023-11-23 Novartis Ag Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
EP4406553A1 (en) 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
WO2024156841A1 (en) 2023-01-27 2024-08-02 Fresenius Kabi Deutschland Gmbh Biopharmaceutical composition
CN117843778B (zh) * 2023-12-21 2024-07-26 北京贝来药业有限公司 针对白介素家族成员的新型纳米抗体及其产品和应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
ES2229264T5 (es) 1995-03-23 2009-12-17 Immunex Corporation Receptor il-17.
WO1997004097A2 (en) * 1995-07-19 1997-02-06 Genetics Institute, Inc. Human ctla-8 and uses of ctla-8-related proteins
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
DK0862454T3 (da) 1995-10-27 2002-12-30 Schering Corp CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
WO1998023284A1 (en) 1996-11-27 1998-06-04 Immunex Corporation Method of regulating nitric oxide production
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
US6635443B1 (en) 1997-09-17 2003-10-21 Human Genome Sciences, Inc. Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
EP1044022B1 (en) 1997-11-10 2006-03-15 Cytimmune Sciences, Inc. Compositions and methods for targeted delivery of factors
US6562578B1 (en) 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
WO1999032632A1 (en) 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
JP2003502006A (ja) 1998-01-09 2003-01-21 イミュネックス・コーポレーション Ｉｌ−１７ｒｈｄｎａ及びポリペプチド
WO1999035267A1 (en) 1998-01-09 1999-07-15 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
EP1056842A2 (en) 1998-02-11 2000-12-06 Maxygen, Inc. Genetic vaccine vector engineering
ES2292242T5 (es) 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
IL141869A0 (en) 1998-09-17 2002-03-10 Zymogenetics Inc Mammalian transforming growth factor beta-9 (ztgfss9)
WO2000020593A1 (en) 1998-10-02 2000-04-13 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
JP2000186046A (ja) * 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
DE29820466U1 (de) 1998-11-16 1999-04-08 Reutter, Werner, Prof. Dr.med., 14195 Berlin Rekombinante Glycoproteine und sie enthaltende Arzneimittel
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
HU229122B1 (en) 1999-01-11 2013-08-28 Merck Sharp & Dohme Corp Rahway Interleukin-17 related mammalian cytokines, polynucleotides encoding them uses
AR022237A1 (es) 1999-01-11 2002-09-04 Schering Corp Citoquinas mamiferas purificadas; reactivos y metodos relacionados
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
MXPA01008110A (es) 1999-02-12 2002-10-23 Scripps Research Inst Metodos para el tratamiento de tumores y metastasis utilizando una combinacion de terapias anti-angiogenicas e inmunoterapia.
EP1053751A1 (en) 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
US6036128A (en) 1999-05-17 2000-03-14 Common Ground Recycling, Inc. Tire shredding machine and method of using the same
WO2001015728A1 (en) 1999-08-27 2001-03-08 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
JP2001086046A (ja) * 1999-09-09 2001-03-30 Nec Corp カメラ付き携帯電話装置
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
DE60143798D1 (de) 2000-06-16 2011-02-17 Cambridge Antibody Tech Immunspezifisch bindende antikörper gegen blys
ES2277947T3 (es) 2000-10-13 2007-08-01 Eli Lilly And Company Procedimientos de uso de un polipeptido afin a il-17 humana para tratar enfermedades.
CA2425506A1 (en) * 2000-10-18 2002-08-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
DE60239450D1 (de) 2001-01-25 2011-04-28 Zymogenetics Inc Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
PT1391464E (pt) * 2001-04-27 2007-11-15 Kirin Pharma Kk Anticorpo monoclonal anti-cd40
WO2003055979A2 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
EP1545578A4 (en) 2002-08-28 2010-07-07 Immunex Corp COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASES
CA2526398C (en) * 2003-05-21 2014-07-15 Medarex, Inc. Human monoclonal antibodies against bacillus anthracis protective antigen
CA2544920C (en) 2003-11-21 2012-09-11 Celltech R & D Limited Method for the treatment of multiple sclerosis by inhibiting il-17 activity
WO2005108616A1 (en) * 2004-05-03 2005-11-17 Schering Corporation Use of il-17 expression to predict skin inflammation; methods of treatment
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP2322219A3 (en) 2005-09-01 2013-06-05 Merck Sharp & Dohme Corp. Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease

Also Published As

Publication number Publication date
NO20070985L (no) 2007-03-30
HRP20181069T1 (hr) 2018-09-07
EP2902039B1 (en) 2018-04-11
PL2364729T3 (pl) 2014-10-31
CY1120723T1 (el) 2019-12-11
LTC1776142I2 (lt) 2022-07-11
EP2364729A3 (en) 2012-01-18
SG155186A1 (en) 2009-09-30
TNSN07034A1 (en) 2008-06-02
SI2902039T1 (en) 2018-07-31
AU2005268857B2 (en) 2010-01-28
PL2366405T3 (pl) 2015-08-31
AR050200A1 (es) 2006-10-04
GB0417487D0 (en) 2004-09-08
US9765140B2 (en) 2017-09-19
HK1207559A1 (en) 2016-02-05
NL300749I2 (nl) 2017-11-02
HRP20110758T1 (en) 2011-11-30
LUC00088I2 (el) 2018-12-17
CY2018027I1 (el) 2020-05-29
EP1776142B9 (en) 2016-09-07
ES2367440T9 (es) 2021-04-28
KR20080029018A (ko) 2008-04-02
NO2015023I2 (no) 2015-10-26
PL2902039T3 (pl) 2018-09-28
BR122018075556B1 (pt) 2022-10-18
MX2007001338A (es) 2008-03-11
DK2364729T6 (en) 2015-07-06
CA2573586A1 (en) 2006-02-09
ES2487533T3 (es) 2014-08-21
PT2902039T (pt) 2018-07-17
CA2573586C (en) 2013-06-25
NO341384B1 (no) 2017-10-30
SI2364729T1 (sl) 2014-08-29
JP2008507988A (ja) 2008-03-21
WO2006013107A1 (en) 2006-02-09
EP1776142B3 (en) 2015-06-24
NO337129B1 (no) 2016-01-25
LTPA2015029I1 (lt) 2022-07-11
DK2366405T3 (en) 2015-05-11
ES2487533T7 (es) 2015-07-14
PT2366405E (pt) 2015-06-30
US20190270804A1 (en) 2019-09-05
BRPI0513078C1 (pt) 2021-05-25
CN101001645A (zh) 2007-07-18
MY144925A (en) 2011-11-30
BRPI0513078B1 (pt) 2019-02-19
AU2010201689A1 (en) 2010-05-20
JP4682200B2 (ja) 2011-05-11
CY2018027I2 (el) 2020-05-29
NO2016017I1 (no) 2016-08-23
PT2364729E (pt) 2014-09-01
NO348010B1 (no) 2024-06-17
LU92768I2 (fr) 2015-11-03
PT1776142E (pt) 2011-10-06
BR122017009404B1 (pt) 2022-02-22
IL180717A0 (en) 2007-06-03
HRP20150480T1 (hr) 2015-07-17
US20140079719A1 (en) 2014-03-20
NO336279B1 (no) 2015-07-06
EP2364729B3 (en) 2015-06-24
PL1776142T4 (pl) 2018-04-30
NO2018007I1 (no) 2018-02-14
LTPA2018515I1 (lt) 2018-10-25
SI1776142T1 (sl) 2011-11-30
DK1776142T3 (da) 2011-10-31
HUS1800040I1 (hu) 2018-11-28
HUE025815T2 (en) 2016-04-28
DK2364729T3 (da) 2014-07-21
ZA200700242B (en) 2008-08-27
RU2426741C2 (ru) 2011-08-20
EP1776142B1 (en) 2011-07-27
ATE517924T1 (de) 2011-08-15
CN101001645B (zh) 2012-09-05
PL2364729T6 (pl) 2016-06-30
LT2902039T (lt) 2018-06-25
BRPI0513078B8 (pt) 2019-08-27
IL180717A (en) 2012-07-31
EP3409288A1 (en) 2018-12-05
DK2902039T3 (en) 2018-07-16
EP2902039A1 (en) 2015-08-05
AU2005268857B8 (en) 2010-05-27
CY2015030I1 (el) 2015-11-04
PL1776142T3 (pl) 2011-12-30
NO2015023I1 (no) 2015-11-02
US20170355762A1 (en) 2017-12-14
US10344084B2 (en) 2019-07-09
EP2366405A2 (en) 2011-09-21
AU2010201689B2 (en) 2011-09-29
US20230235038A1 (en) 2023-07-27
SI2366405T1 (sl) 2015-07-31
KR100852523B1 (ko) 2008-08-14
NO2022026I1 (no) 2022-06-24
RU2007108067A (ru) 2008-09-10
US8617552B2 (en) 2013-12-31
HRP20110758T4 (hr) 2015-07-31
FR15C0048I1 (fr) 2015-08-28
US20120107325A1 (en) 2012-05-03
US8119131B2 (en) 2012-02-21
FR15C0048I2 (fr) 2015-11-20
NO337286B1 (no) 2016-02-29
EP2364729B1 (en) 2014-05-14
DK1776142T6 (en) 2015-07-06
US20150152178A1 (en) 2015-06-04
ES2367440T3 (es) 2011-11-03
ES2367440T7 (es) 2015-07-14
US20090280131A1 (en) 2009-11-12
PE20060418A1 (es) 2006-06-15
HK1101277A1 (en) 2007-10-12
US7807155B2 (en) 2010-10-05
CY1115444T1 (el) 2017-01-04
HUE038187T2 (hu) 2018-10-29
MA28982B1 (fr) 2007-11-01
EP2366405B1 (en) 2015-02-25
TR201808057T4 (tr) 2018-06-21
ECSP077198A (es) 2007-02-28
PL1776142T6 (pl) 2016-06-30
TW200617025A (en) 2006-06-01
ES2677245T3 (es) 2018-07-31
TWI359153B (en) 2012-03-01
ES2536228T3 (es) 2015-05-21
AU2005268857A1 (en) 2006-02-09
BRPI0513078A (pt) 2008-04-22
NO20150065L (no) 2007-03-30
US20100215666A1 (en) 2010-08-26
NO20171697A1 (no) 2007-03-30
NO20150064L (no) 2007-03-30
RU2011113153A (ru) 2012-10-20
NZ552658A (en) 2009-11-27
NO20151787L (no) 2006-02-06
HUS1500037I1 (hu) 2017-10-30
EP1776142A1 (en) 2007-04-25
CY2015030I2 (el) 2017-11-14
EP2364729A2 (en) 2011-09-14
RU2426741C3 (ru) 2017-11-15
CY1111963T1 (el) 2015-11-04
AU2005268857C1 (en) 2012-01-19
EP2366405A3 (en) 2012-01-18
HK1256639A1 (zh) 2019-09-27
KR20070036166A (ko) 2007-04-02

Similar Documents

Publication Publication Date Title
CY1116256T1 (el) Il-17 ανταγωνιστικα αντισωματα
CY1107989T1 (el) Ανασυνδυασμενα αντισωματα της ανθρωπινης ιντepλευκινης-1 βητα
CY1123535T1 (el) Υποκαταστατο θεραπευτικο τελικο σημειο για βασιζομενη σε anti-ctla-4 ανοσοθεραπεια ασθενειας
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
CY1117817T1 (el) Υποκατεστημενα ακυλανιλιδια και μεθοδοι χρησης αυτων
CY1115871T1 (el) Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας
CY1108779T1 (el) Αντισωματα για την ανθρωπινη il-1 βητα
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
GEP20115195B (en) Antibodies directed against amyloid-beta peptide and use thereof
RS53318B (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
PE20110797A1 (es) Anticuerpos anti mn
CY1110134T1 (el) Αντισωματα ειδικα για το cd22 και η θεραπευτικη και διαγνωστικη χρηση τους
RS53215B (en) NEUTRAL ANTIBODIES HAVING SPECIFICITY TO HUMAN IL-17
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
ATE530195T1 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
DE602006005526D1 (de) Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
CY1110188T1 (el) Αντισωματα κατα συζυγων φωσφορυλχολινης
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
EA201070888A1 (ru) Антитела и их производные
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
DE602006016413D1 (de) Kim-1-antikörper zur behandlung von th2-vermittelten erkrankungen
CY1107785T1 (el) Χρηση του βασιλιξιμαμπ στη θεραπεια της ρευματοειδους αρθριτιδας ´η νοσων του δερματος
HK1106001A1 (en) Method of screening for a carnitine transporter agonist or antagonist and its uses